Investors of ESSA Pharma Inc. Urged to Participate in Class Action Lawsuit by Rosen Law Firm

ESSA Pharma Inc. Securities Fraud: A Legal Call to Investors

In a significant legal development, the Rosen Law Firm, known for its advocacy for investor rights, is reaching out to individuals who purchased securities of ESSA Pharma Inc. (NASDAQ: EPIX) during the period from December 12, 2023, to October 31, 2024. This outreach is in connection with a class action lawsuit that aims to hold the company accountable for alleged securities fraud.

Important Deadlines and Next Steps

Potential plaintiffs are urged to act swiftly, as there is a crucial deadline approaching on March 25, 2025, for those wishing to serve as lead plaintiffs in this class action. Investors who acquired ESSA Pharma shares between the specified dates could be eligible for compensation without upfront payments through a contingency fee arrangement.

How to Get Involved

To participate in the class action lawsuit, interested parties should visit the Rosen Law Firm's dedicated webpage for this case. Here, investors can fill out a submission form or reach out directly to Phillip Kim, Esq., at the firm’s toll-free number or via email to learn more about their rights and options.

Background of the Case

The lawsuit claims that ESSA Pharma's management, throughout the class period, failed to adequately inform their investors about critical issues regarding their drug masofaniten. Specifically, it is alleged that:
1. The combined treatment of masofaniten and enzalutamide did not demonstrate a clear efficacy advantage over enzalutamide when used alone.
2. Consequently, masofaniten's effectiveness in treating prostate cancer was misrepresented.
3. The anticipated outcomes of the M-E Combination Study were unlikely to meet the primary endpoint established for Phase 2 trials.
4. This resulted in an overstatement of masofaniten's clinical, regulatory, and commercial viability.
5. As a result, public statements made by ESSA Pharma were materially false and misleading.

When the truth emerged, it significantly affected share values, leading to investor losses.

Trust in Experienced Legal Representation

Rosen Law Firm emphasizes the importance of selecting legal counsel with a proven track record in securities litigation. The firm is recognized for its significant settlements in similar cases, including one against a Chinese company, and maintains a high ranking in terms of successful securities class action settlements. Since 2013, the firm has achieved notable recoveries for investors, reaffirming its reputation in the legal field.

Conclusion

For ESSA Pharma investors, this is a crucial moment to engage in legal action that could yield compensation for financial losses due to alleged deception by company officials. The road to recovery begins with the timely filing of claims, ensuring representation by qualified professionals in the legal arena. To stay updated on this case, investors can also follow the Rosen Law Firm on various social media platforms.

In conclusion, if you purchased ESSA Pharma securities within the defined class period, take action now to protect your rights and potentially recover your losses.